MX2011005964A - Conjugados terapeuticos de peptidos y sus usos. - Google Patents

Conjugados terapeuticos de peptidos y sus usos.

Info

Publication number
MX2011005964A
MX2011005964A MX2011005964A MX2011005964A MX2011005964A MX 2011005964 A MX2011005964 A MX 2011005964A MX 2011005964 A MX2011005964 A MX 2011005964A MX 2011005964 A MX2011005964 A MX 2011005964A MX 2011005964 A MX2011005964 A MX 2011005964A
Authority
MX
Mexico
Prior art keywords
peptide therapeutic
therapeutic conjugates
peptide
compound
linker
Prior art date
Application number
MX2011005964A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Gagnon
Jean-Paul Castaigne
Betty Lawrence
Michael Demeule
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of MX2011005964A publication Critical patent/MX2011005964A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
MX2011005964A 2008-12-05 2009-12-07 Conjugados terapeuticos de peptidos y sus usos. MX2011005964A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20094708P 2008-12-05 2008-12-05
PCT/CA2009/001781 WO2010063124A1 (en) 2008-12-05 2009-12-07 Peptide therapeutic conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2011005964A true MX2011005964A (es) 2011-09-01

Family

ID=42232848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011005964A MX2011005964A (es) 2008-12-05 2009-12-07 Conjugados terapeuticos de peptidos y sus usos.

Country Status (11)

Country Link
US (2) US20110288011A1 (https=)
EP (1) EP2794663A1 (https=)
JP (1) JP2012510798A (https=)
CN (2) CN102348723A (https=)
AU (1) AU2009322045A1 (https=)
BR (1) BRPI0923283A2 (https=)
CA (1) CA2745499A1 (https=)
MX (1) MX2011005964A (https=)
RU (1) RU2011125366A (https=)
WO (1) WO2010063124A1 (https=)
ZA (1) ZA201104497B (https=)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
RU2408605C2 (ru) 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
ES2744225T3 (es) 2005-07-15 2020-02-24 Angiochem Inc Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
JP2010506860A (ja) 2006-10-19 2010-03-04 アンジオケム，インコーポレーテッド Ｐ−糖タンパク質機能を刺激するための化合物およびその使用
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CA2740316A1 (en) * 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8853353B2 (en) 2008-12-17 2014-10-07 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
RU2012103240A (ru) * 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
WO2011070573A1 (en) * 2009-12-07 2011-06-16 Ben-Gurion University Of The Negev Research And Development Authority Antimicrobial water treatment membranes and production thereof
AU2010327949A1 (en) * 2009-12-11 2012-06-28 Case Western Reserve University Insulin analogues with chlorinated amino acids
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
EP2694083A2 (en) * 2011-04-01 2014-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
JP6144673B2 (ja) 2011-06-03 2017-06-07 オフィディオン インコーポレイティド 血液脳関門を通過して輸送するための組成物及び方法
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
CU24076B1 (es) * 2011-09-30 2015-01-29 Ct De Ingeniería Genética Y Biotecnología Composición para el control de patógenos
CN104145015A (zh) * 2011-12-01 2014-11-12 安吉奥开米公司 靶向的溶酶体酶化合物
BR112014013250A2 (pt) * 2011-12-01 2019-09-24 Angiochem Inc compostos com enzima alvo e usos dos mesmos
US20150025002A1 (en) * 2012-01-12 2015-01-22 University Of Ulster Peptides and peptide derivatives based on xenin
WO2013173337A2 (en) * 2012-05-15 2013-11-21 Seattle Genetics, Inc. Self-stabilizing linker conjugates
AU2013273894A1 (en) * 2012-06-15 2015-02-05 Angiochem Inc. Targeted iduronidase compounds
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
BR112015030356A2 (pt) 2013-06-10 2017-12-05 Ipierian Inc métodos de tratamento de uma taupatia
BR112016010454A2 (pt) 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
EP3094642B1 (en) 2013-12-20 2018-03-21 Tikomed AB Surface-binding peptide
US20170253643A1 (en) * 2014-09-02 2017-09-07 Tokyo University Of Science Foundation Centrally-Acting Peptide Derivative, and Pharmaceutical Composition
ES2748117T3 (es) * 2015-04-22 2020-03-13 Euroimmun Medizinische Labordiagnostika Ag Diagnóstico de una nueva enfermedad autoinmune
IL293655B2 (en) * 2015-05-27 2025-04-01 Univ Northwestern Modified carbohydrate particles and particulate compositions for modulating immune response
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
US10858410B2 (en) * 2015-08-12 2020-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
CN106466475B (zh) * 2015-08-21 2021-06-08 中国人民解放军军事医学科学院毒物药物研究所 抗菌肽与聚合物结合而成的复合物、其制备方法及用途
KR102863433B1 (ko) 2015-12-16 2025-09-23 다이어트4라이프 에이피에스 식이 펩타이드
US11530243B2 (en) * 2016-02-18 2022-12-20 Veiove Animal Health Inc. Non-cleavable substance P conjugates and methods of use thereof
US10973812B2 (en) 2016-03-03 2021-04-13 Regents Of The University Of Minnesota Ataxia therapeutic compositions and methods
EP3452510A4 (en) 2016-04-04 2020-01-15 Bioverativ USA Inc. ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF
WO2017181277A1 (en) 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
CN105801709B (zh) * 2016-04-29 2019-10-08 北京纽莱福生物科技有限公司 CBLB502-Fc融合蛋白及其制备方法
TWI851531B (zh) 2016-08-09 2024-08-11 美商思進公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
US20190352335A1 (en) * 2016-12-19 2019-11-21 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
JP7295838B2 (ja) * 2017-07-13 2023-06-21 シティ・オブ・ホープ ホスホロチオエートコンジュゲートペプチド及びその使用方法
FR3070264A1 (fr) * 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019043382A1 (en) * 2017-08-31 2019-03-07 University Of Dundee DERIVED LEPTIN PEPTIDES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CN107964047B (zh) * 2017-12-18 2018-11-02 哈尔滨工业大学 基于内吗啡肽-1和神经降压素(8-13)的嵌合肽及其合成方法和应用
CN110337302B (zh) * 2018-01-15 2023-07-21 深圳市星银医药有限公司 一种马栗树提取物和利那洛肽组合物
NZ766762A (en) * 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
CN108490178B (zh) * 2018-02-13 2019-08-30 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于npc诊断及预后预测的标志物及其应用
KR102250412B1 (ko) 2018-05-04 2021-05-17 트윈피그바이오랩(주) 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화
EP3843768A4 (en) 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS
CA3142871A1 (en) * 2019-06-06 2020-12-10 Aroa Biosurgery Limited Bioactive agents and methods related thereto
KR20220042129A (ko) 2019-06-26 2022-04-04 마이클 이. 셀스테드 신규한 세타 디펜신 유사체(novel theta defensin analogs)
CN112279921B (zh) * 2019-07-11 2025-07-29 厦门大学 用于胞内递送分子的复合物
CN110420317B (zh) * 2019-07-25 2022-11-22 中国人民解放军军事科学院军事医学研究院 Cblb502蛋白在防治创伤后应激障碍中的应用
CN110437308B (zh) * 2019-08-20 2023-05-05 倪京满 一类对铜绿假单胞菌具有特异活性的含β氨基酸的抗菌肽类似物及其应用
CN110563802B (zh) * 2019-09-04 2023-04-07 倪京满 一组含n-甲基化氨基酸及n端脂肪酸修饰的抗菌肽类似物及其合成方法和应用
CN111808168A (zh) * 2020-07-21 2020-10-23 南京农业大学 一类褐飞虱硫激肽类似物的合成及应用
CN111704651B (zh) * 2020-07-27 2021-10-08 南京安吉生物科技有限公司 具有抗衰老作用的多肽rv3和rv4及其应用
CN114057831B (zh) * 2020-08-07 2024-03-12 三凡生技研发股份有限公司 促进血管增生的短链胜肽及其促进糖尿病伤口愈合的用途
KR20220076375A (ko) * 2020-11-30 2022-06-08 세종대학교산학협력단 신규 퇴행성 신경질환 치료용 약학적 조성물
CN112656953A (zh) * 2020-12-30 2021-04-16 重庆医科大学 凝血酶响应型双靶向脂质体及其制备方法和应用
CN112851789B (zh) * 2021-02-04 2022-10-18 大理大学 一种脑靶向hiv进入抑制剂多肽及其应用
AU2022222778A1 (en) * 2021-02-22 2023-08-31 Yale University Targeted bifunctional degraders and methods using same
CN113651874B (zh) * 2021-08-02 2023-02-10 上海大学 一种具有抑制念珠菌生长繁殖作用的订书肽及其制备方法和应用
KR102819567B1 (ko) * 2021-11-24 2025-06-13 주식회사 윙스타바이오 아밀로이드 전구체 단백질에 대한 저해 활성을 갖는 펩타이드 및 이의 용도
CN114250204B (zh) * 2021-12-29 2024-02-09 深圳瑞德林生物技术有限公司 一种羧酸还原酶突变体及酶法合成脱羧肌肽的方法
WO2023143463A1 (en) * 2022-01-30 2023-08-03 Nanjing Reju Therapeutics , Inc. Fusion protein and application thereof
CN119654336A (zh) * 2022-05-16 2025-03-18 儿童医疗中心有限公司 治疗心脏病的组合物和方法
CN115286694B (zh) * 2022-06-02 2024-08-20 温州医科大学 一种南美青蛙宿主防御肽的衍生肽ps-pt-6f及其制备方法和应用
CN115806740B (zh) * 2022-11-17 2024-01-30 四川大学 一种集成多模态响应的导电水凝胶及其制备方法和用途
CN116036234B (zh) * 2023-01-17 2024-02-06 青岛市中心医院 一种用于治疗骨质疏松的药剂
CN115948069B (zh) * 2023-02-09 2024-11-29 广州工业智能研究院 一种双重抗菌超疏液涂层及其制备方法
CN116298281A (zh) * 2023-03-27 2023-06-23 山西农业大学 一种基于距离信号读出的胰蛋白酶含量检测方法
CN116333041A (zh) * 2023-04-10 2023-06-27 湖南中晟全肽生化有限公司 一种激活grp受体的多肽化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052814A1 (en) * 1998-09-28 2004-03-18 Wenyuan Shi Fusion proteins for targeted delivery of antimicrobial peptides
US20040162284A1 (en) * 2003-02-19 2004-08-19 Harris Herbert W. Method of lowering body temperature with (S) tofisopam
RU2408605C2 (ru) * 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
CN101511868B (zh) * 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
AU2008255556B2 (en) * 2007-05-29 2014-08-07 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues

Also Published As

Publication number Publication date
ZA201104497B (en) 2012-09-26
EP2794663A4 (en) 2014-10-29
CN103665170A (zh) 2014-03-26
US20160263235A1 (en) 2016-09-15
RU2011125366A (ru) 2013-01-10
AU2009322045A1 (en) 2011-07-07
CN102348723A (zh) 2012-02-08
WO2010063124A1 (en) 2010-06-10
US20110288011A1 (en) 2011-11-24
JP2012510798A (ja) 2012-05-17
EP2794663A1 (en) 2014-10-29
BRPI0923283A2 (pt) 2017-06-06
CA2745499A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
MX2011005964A (es) Conjugados terapeuticos de peptidos y sus usos.
MX2011005963A (es) Conjugados de neurotensina o analogos de neurotensina y sus usos.
MX2011005965A (es) Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
EA201070786A1 (ru) Бензофуропиримидиноны
MX2012000016A (es) Conjugados de peptidos multimericos y sus usos.
EA201170441A1 (ru) Терапевтические противовирусные пептиды
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
UY32730A (es) Inhibidores de cyp17
TN2011000291A1 (en) Purine compounds
GT201100181A (es) "inhibidores de proteina cinasa"
DOP2012000011A (es) Formulacion farmaceutica
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
BRPI0721213A2 (pt) "regime de dosagem de inibidores da comt"
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
ECSP12012290A (es) Formulaciones farmacéuticas
EA201270590A1 (ru) Ингибиторы акт
EA201190125A1 (ru) Таблетки для комбинированной терапии
CY1114883T1 (el) Καινοφανεις αντιβακτηριακοι παραγοντες για την αγωγη των κατα gram θετικων λοιμωξεων
WO2009124962A3 (en) Sulfonamides
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
TN2012000105A1 (en) Spirolactam derivatives and uses of same
EA201270728A1 (ru) Пуриновые соединения
MY157533A (en) Effervescent compositions